{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-121819","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.308719+00:00","generated_at":"2026-05-16T12:54:13.545011+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sagimet enters global exclusive license with TAPI for innovative resmetirom API for FDC program","bullets":["License grants Sagimet exclusive global rights to TAPI's innovative forms of resmetirom API for fixed-dose combination with denifanstat.","Sagimet paid $2.5M upfront; TAPI may receive low single-digit royalties and up to $5.5M in manufacturing milestones.","Phase 1 PK trial of denifanstat + resmetirom underway; topline data expected by end of 2025.","Sagimet plans to select one TAPI resmetirom form for a single FDC tablet for Phase 3 study in H2 2026.","Combination targets MASH cirrhosis (F4) where no approved therapies exist."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-121819","json":"https://secwatch.observer/filing/0001104659-25-121819.json","markdown":"https://secwatch.observer/filing/0001104659-25-121819.md","text":"https://secwatch.observer/filing/0001104659-25-121819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/0001104659-25-121819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/tm2533462d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:54:13.545011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}